NYMOX PHARMACEUTICAL CORP
Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a focus on products targeted for the unmet needs of the rapidly aging male population. Their lead drug candidate, Fexapotide Triflutate (FT), has completed Phase 3 development for BPH. The company is also developing FT for early-stage prostate cancer (PCA). Nymox is preparing for regulatory approval filings in major economies.
Registre Officiel
Dernière vérification: 1/2/2026
Analyse Qualité IA
Détails du Score de Confiance
Liens Rapides
Points forts du site
🌟 Entreprises similaires de confiance
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals is dedicated to advancing science to improve the lives of individuals, with an initial focus on hereditary angioedema (HAE). They are developing orally-delivered small molecule medicines to transform the HAE treatment landscape and address unmet patient needs. Their goal is to make a meaningful difference for people living with HAE by offering new possibilities for disease management. KalVista's lead product is an oral on-demand treatment for HAE.
Harmony Biosciences Holdings, Inc.
Harmony Biosciences is a pharmaceutical company focused on developing and delivering innovative therapies for rare neurological diseases. They specialize in treatments for sleep/wake disorders, neurobehavioral conditions, and rare epilepsies. With a commitment to empathy and innovation, they aim to improve the lives of patients by addressing unmet medical needs and advancing patient-kind through novel treatments.
Novo Nordisk A/S
Novo Nordisk is a global pharmaceutical company focused on treating diabetes, obesity, and other serious chronic diseases. They offer innovative medicines and delivery systems, holding a leading position in diabetes care. The company is committed to sustainable development and patient access.